{"filing":{"accession_number":"0001654954-26-009036","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"a5712z.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426009036/a5712z.htm"},"events":[{"id":36029,"run_id":33217,"accession_number":"0001654954-26-009036","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This 6-K discloses FDA approval of Jemperli (dostarlimab) as the first and only immunotherapy for MSI-H/dMMR locally advanced rectal cancer, based on positive AZUR-1 trial data showing 68% of patients achieved sustained clinical complete responses at 12 months with no disease recurrences reported among responders after median follow-up exceeding two years. This is a material regulatory and commercial milestone for GSK's oncology portfolio that would affect a reasonable investor's assessment of the company's product pipeline and revenue prospects, but does not fit a discrete event category (not an earnings release, M\u0026A activity, executive change, or other named type) and is therefore best classified as an operational milestone—specifically a material product approval and regulatory achievement.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-10-19","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":40299,"accession_number":"0001654954-26-009036","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This 6-K discloses FDA approval of Jemperli (dostarlimab) as the first and only immunotherapy for MSI-H/dMMR locally advanced rectal cancer, based on positive AZUR-1 trial data showing 68% of patients achieved sustained clinical complete responses at 12 months with no disease recurrences reported among responders after median follow-up exceeding two years. This is a material regulatory and commercial milestone for GSK's oncology portfolio that would affect a reasonable investor's assessment of the company's product pipeline and revenue prospects, but does not fit a discrete event category (not an earnings release, M\u0026A activity, executive change, or other named type) and is therefore best classified as an operational milestone—specifically a material product approval and regulatory achievement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T17:07:37.793388+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-10-19"}]}